5 Oversold Global Stocks To Buy

In this piece, we will take a look at five oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 10 Oversold Global Stocks To Buy.

5. Mesoblast Limited (NASDAQ:MESO)

Latest 14 Day RSI Score: 18.06

Mesoblast Limited (NASDAQ:MESO) is an Australian biotechnology company that is headquartered in Melbourne. It is a penny stock whose shares were in for a tough time in the market as August started and the FDA rejected its therapy for complications arising from bone marrow transplant.

Only two out of the 943 hedge funds part of Insider Monkey’s database had invested in Mesoblast Limited (NASDAQ:MESO) during Q1 2023. Out of these, the largest is Israel Englander’s Millennium Management which owns a $967,000 stake.

4. Clarivate Plc (NYSE:CLVT)

Latest 14 Day RSI Score: 17.98

Clarivate Plc (NYSE:CLVT) is a British technology firm that provides analytics, planning, and other services to firms engaging in scientific research. It beat analyst EPS estimates for its second quarter of 2023 earnings, and the shares are rated Buy on average.

As of March 2023, 45 of the 943 hedge funds polled by Insider Monkey had bought a stake in the firm. Clarivate Plc (NYSE:CLVT)’s largest hedge fund shareholder is Leonard Green’s Leonard Green & Partners with an investment worth $1 billion.

3. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

Latest 14 Day RSI Score: 17.82

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is an Israeli firm that focuses on developing treatments for people suffering from hepatitis and other liver diseases that are generally a result of other serious diseases such as HIV. The stock was in for some good news in July after receiving a Buy upgrade, but overall, analyst sentiment has waned over the years.

Insider Monkey dug through 943 hedge fund portfolios for their first quarter of 2023 shareholdings to discover that four had invested in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD). Mark Lampert’s Biotechnology Value Fund / BVF Inc is the largest shareholder out of these, with a $574,818 stake.

2. Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Latest 14 Day RSI Score: 16.27

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) is a Canadian firm that is developing treatments for tumors and for causes of tumors such as DNA damage. It missed first quarter EPS estimates by a wide margin, and analysts expect a 39 cent loss for the second quarter.

Insider Monkey’s Q1 2023 survey of 943 hedge funds revealed that 14 had held the firm’s shares. Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)’s biggest investor in our database is David Witzke and Michael Gregory’s Avidity Partners Management since it owns 5.7 million shares that are worth $21.4 million.

1. Neonode Inc. (NASDAQ:NEON)

Latest 14 Day RSI Score: 14.29

Neonode Inc. (NASDAQ:NEON) is a Swedish technology company that develops products that enable video stream service providers to track objects during streams. The shares have seen little attention from analysts lately, and the stock price has more than halved this year.

During this year’s first quarter, three of the 943 hedge funds part of Insider Monkey’s database had invested in Neonode Inc. (NASDAQ:NEON). Jim Simons’ Renaissance Technologies is the largest shareholder with a stake of $502,000.

Disclosure: None. You can also take a look at 15 Most Valuable Canadian Companies and 10 Most Profitable Small Businesses in 2023.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Follow Insider Monkey on Twitter